Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × nintedanib × CNS × Clear all

Phase

Status

Completed 2 Terminated 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 5 Gastrointestinal 3 Other solid neoplasm 2 Gynecologic 2 Sarcoma 1 CNS 1 Breast 1

Conditions

Interventions

Temozolomide 80 Radiotherapy 41 Bevacizumab 34 Radiosurgery 22 Magnetic Resonance Spectroscopy 19 Cyclophosphamide 17 Radiation 14 Irinotecan 13 Carboplatin 12 Topotecan 11 Nivolumab 10 Lomustine 10 Filgrastim 10 Everolimus 10 Etoposide 10 Erlotinib Hydrochloride 10 Radiotherapy, Intensity-Modulated 9 pembrolizumab 8 Ipilimumab 8 Granulocyte Colony-Stimulating Factor 8 antineoplaston AS 2-1 7 antineoplaston A10 7 Surgical Procedures, Operative 7 Mental Status and Dementia Tests 7 Isotretinoin 7 Granulocyte-Macrophage Colony-Stimulating Factor 7 Carmustine 7 sargramostim 6 Vincristine 6 TPI-287 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01666600 2017-11-01

NOA-12: BIBF1120 and R-RT in Glioblastoma

University Hospital Heidelberg

Phase 1/2 Terminated

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡